KalVista is a pharmaceutical company focused on the discovery, development and commercialization
of small molecule protease inhibitors as new treatments for diseases with significant
KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema
(HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity
is implicated, but where there remains substantial unmet clinical need.
KalVista continues to investigate additional proteases as potential therapeutic targets to
fully exploit its research expertise and expand its portfolio.
The Company features an R&D team with an established track record in the pharmaceutical development
of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein
in disease, and a management team with proven experience in bringing small molecules through the
clinic to commercialization.
KalVista Pharmaceuticals Appoints Edward P. Feener, Ph.D. as Chief Scientific Officer